TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2449506
Drug: 1000 mg
Normalized name: bran 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg vancomycin infused over 1 h
Study: 2449506
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg vancomycin infused over 1 h
Study: 31161343
Drug: Lacunar infarct
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lacunar infarct with concurrent embolic infarcts
Study: 29555621
Drug: Mobile Insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mobile Insulin Titration Intervention (MITI) program
Study: 28919708
Drug: AOS group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: AOS group (AG, oral administration 10‐mg AOS daily)
Study: 28919708
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (CG, placebo daily)
Study: 19264879
Drug: Home-based Behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home-based Behavioral Family Systems Therapy (BFST)
Study: 15585437
Drug: Morphine sulfate
Normalized name: Morphine Sulfate
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Morphine sulfate 7.5 mg
Study: 9549739
Drug: Intrathecal opioids
Normalized name: beractant
DrugBank: Beractant (DB06761)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intrathecal opioids (morphine and sufentanil) administered at L3-L4 after induction of anaesthesia
Study: 9549739
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (inhalation and intravenous narcotic anaesthesia)
Study: 8559866
Drug: Tricyclic Antidepressant
Normalized name: Tricyclic antidepressant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tricyclic Antidepressant Medication
Study: 2713219
Drug: Oral paracetamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral paracetamol (1 g)
Study: 2713219
Drug: Oral chloramphenicol
Normalized name: Chloramphenicol
DrugBank: Chloramphenicol succinate (DB07565)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral chloramphenicol (500 mg)
Study: 30418227
Drug: Antibiotics without
Normalized name: threonine
DrugBank: Threonine (DB00156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Antibiotics without L-carnitine (control)
Study: 28641912
Drug: Spirited Life
Normalized name: TURPENTINE SPIRITS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spirited Life intervention (2-year multicomponent health intervention including personal goal setting, monthly health coaching, online weight loss intervention, small grant, and workshops)
Study: 21623982
Drug: Trazodone 50
Normalized name: traZODone 50 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trazodone 50 mg administered 30 min before bedtime for 7 days
Study: 16792770
Drug: Efalizumab 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Efalizumab 1.0 mg kg‐1 once weekly for 12 weeks
Study: 12125616
Drug: Testosterone injections
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone injections
Study: 1287015
Drug: 0.4 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4 mg/kg of famotidine (Group 3)
Study: 1287015
Drug: 0.4 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4 mg/kg of famotidine (Group 6)
Study: 1287015
Drug: 0.4 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4 mg/kg of diphenhydramine (Group 2)
Study: 1287015
Drug: No drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: No drugs (Group 1)
Study: 4075934
Drug: Maternal caffeine
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Maternal caffeine ingestion (500 mg/day)
Study: 30165610
Drug: Canakinumab 50
Normalized name: Canakinumab
DrugBank: Canakinumab (DB06168)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Canakinumab 50 mg, 150 mg, or 300 mg subcutaneously once every 3 months
Study: 18453793
Drug: 8-item medication
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 8-item medication adherence scale
Study: 12649700
Drug: Lornoxicam 8
Normalized name: lornoxicam 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lornoxicam 8 mg bid
Study: 11400948
Drug: Thalidomide (200-800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thalidomide (200-800 mg/day)
Study: 9489600
Drug: Valaciclovir, 1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valaciclovir, 1000 mg, given alone
Study: 9489600
Drug: Valaciclovir, 1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valaciclovir, 1000 mg, given with digoxin
Study: 9489600
Drug: Digoxin given
Normalized name: Digoxin
DrugBank: Digoxin (DB00390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Digoxin given with valaciclovir (1000 mg three times/day for 8 days)
Study: 3361221
Drug: Metronidazole 400
Normalized name: metronidazole 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metronidazole 400 mg twice daily
Study: 29098392
Drug: Dexmedetomidine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine infusion (6 µg/kg/h over 10 min followed by 0.2‐0.7 µg/kg/h)
Study: 29098392
Drug: Target-controlled infusion
Normalized name: Diphtheria toxin-il-3 fusion protein targeting IL-3 receptor
DrugBank: Tagraxofusp (DB14731)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Target-controlled infusion (initial target of 1.5 ng/ml using the Dyck model)
Study: 16441950
Drug: Isoflavone supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isoflavone supplementation (50 mg/d)
Study: 6282434
Drug: MER (methanol-extraction
Approvals — FDA: no, EMA: no, PMDA: no
Description: MER (methanol-extraction residue of Bacillus Calmette-Guerin) 400 mcg intradermally every six weeks
Study: 30536595
Drug: sacubitril/valsartan 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: sacubitril/valsartan 200 mg and 400 mg
Study: 10955425
Drug: Monitoring plasma
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monitoring plasma glucose up to four times daily
Study: 6337655
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose bolus 6‐methylprednisolone (BMPr) at 20 mg/kg/day i.v. for the first 3 days, 10 mg/kg/day i.v. for the following 4 days, then tapered to 1 mg/kg/day.
Study: 6337655
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose bolus 6‐methylprednisolone (BMPr)
Study: 30064027
Drug: Tumor Treating
Normalized name: human breast tumor cell
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tumor Treating Fields (TTF) therapy
Study: 24756515
Drug: Lorazepam (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lorazepam (0.1 mg/kg IV, repeat at 5 minutes if necessary)
Study: 24756515
Drug: Diazepam (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam (0.2 mg/kg IV, repeat at 5 minutes if necessary)
Study: 24756515
Drug: Lorazepam (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lorazepam (0.1 mg/kg IV)
Study: 12524668
Drug: 75 g
Normalized name: Zosyn 3.375 GM Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 g glucose given to fed subjects
Study: 12524668
Drug: 75 g
Normalized name: Zosyn 3.375 GM Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 g glucose given to 4-day-fasted subjects
Study: 12524668
Drug: 33 g
Normalized name: lancets 33 gauge MISCELL EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: 33 g glucose in OGTT for 13-hour-fasted subjects
Study: 12524668
Drug: 100 g
Normalized name: Berri-Freez 4.5 GM per 100 GM
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 g glucose in OGTT for 13-hour-fasted subjects
Study: 10472349
Drug: Docetaxel/Irinotecan at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Docetaxel/Irinotecan at dose level 1 (20/25 mg/m2)
Study: 10472349
Drug: Docetaxel/Irinotecan at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Docetaxel/Irinotecan at dose level 2 (20/40 mg/m2)
Study: 10472349
Drug: Docetaxel/Irinotecan at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Docetaxel/Irinotecan at dose level 3 (25/55 mg/m2)
Study: 10472349
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment (Docetaxel/Irinotecan with radiotherapy)
Study: 2060716
Drug: High fasting
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High fasting plasma insulin concentration and low 2-h plasma insulin concentration after a glucose load
Study: 22760800
Drug: 0.1% riboflavin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1% riboflavin (w/v) eyedrops in 20% dextran solution for 1 month
Study: 17993041
Drug: Modafinil 200,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modafinil 200, 300, or 400 mg once daily for up to 12 weeks
Study: 15598674
Drug: Pioglitazone (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pioglitazone (30 mg/d, n = 25)
Study: 15598674
Drug: Metformin (850
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (850 mg three times daily, n = 27)
Study: 8427821
Drug: Topical betamethasone-17-valerate
Normalized name: Betamethasone Valerate
DrugBank: Betamethasone (DB00443)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical betamethasone-17-valerate
Study: 3669078
Drug: No‐Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No‐Treatment
Study: 31043129
Drug: High-load resistance
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-load resistance training (HL-RT, e.g. 70% of 1 repetition-maximum, 1RM)
Study: 31043129
Drug: Low-load resistance
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-load resistance training with partial blood flow restriction (LL-BFR, e.g. 20% 1RM)
Study: 28238522
Drug: Standard care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard care plus endovascular treatment
Study: 21813857
Drug: DENV vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: DENV vaccine (34 subjects; four received 1/10th dose)
Study: 21813857
Drug: Control vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control vaccine (17 subjects; dose 1: live varicella; dose 2: Haemophilus influenzae type b)
Study: 19356272
Drug: Regular-energy orangeade
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular-energy orangeade with large sips (20 g/sip)
Study: 19356272
Drug: Regular-energy orangeade
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular-energy orangeade with small sips (5 g/sip)
Study: 19356272
Drug: No-energy orangeade
Approvals — FDA: no, EMA: no, PMDA: no
Description: No-energy orangeade with large sips (20 g/sip)
Study: 19356272
Drug: No-energy orangeade
Approvals — FDA: no, EMA: no, PMDA: no
Description: No-energy orangeade with small sips (5 g/sip)
Study: 8995749
Drug: 1 alpha
Normalized name: antiCD11 alpha
DrugBank: Efalizumab (DB00095)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 1 alpha (OH)‐vitamin D2, 4 micrograms/day or 4 micrograms thrice weekly, adjusted over 12 weeks
Study: 3680575
Drug: Microencapsulated KCl
Normalized name: potassium chloride
DrugBank: Potassium chloride (DB00761)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Microencapsulated KCl capsule preparation
Study: 3680575
Drug: Wax-matrix formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wax-matrix formulation
Study: 3680575
Drug: New microencapsulated
Approvals — FDA: no, EMA: no, PMDA: no
Description: New microencapsulated KCl tablet preparation
Study: 27143690
Drug: Temsirolimus (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Temsirolimus (25 mg weekly)
Study: 21360491
Drug: Rituximab (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rituximab (2 × 500 mg intravenously)
Study: 18165599
Drug: Ropivacaine 90
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine 90 mg (9 mL), morphine 4 mg (10 mL), and ketorolac 30 mg (1 mL) (total volume 20 mL)
Study: 20880596
Drug: Saline (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline (20 mL)
Study: 18165599
Drug: IV ketorolac
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV ketorolac 30 mg (1 mL)
Study: 18165599
Drug: IV saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV saline (1 mL)
Study: 12948794
Drug: Carbocaine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbocaine (10 mg/ml)
Study: 7521662
Drug: Autologous bone
Normalized name: Human autologous bone marrow derived osteoblastic cells
DrugBank: Human autologous bone marrow derived osteoblastic cells (DB18259)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous bone marrow transplantation (ABMT) with high-dose melphalan, and additional treatments including fractionated total body irradiation, hemi-body irradiation, and high-dose etoposide.
Study: 2511684
Drug: 5 x
Normalized name: PAD,ABDOMINAL 5 X 9 STERILE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 x 2.5 mg isosorbide dinitrate (ISDN)
Study: 2511684
Drug: 5 x
Normalized name: PAD,ABDOMINAL 5 X 9 STERILE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 x 40 mg isosorbide dinitrate (ISDN)
Study: 2511684
Drug: Low-dose ISDN
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose ISDN
Study: 2511684
Drug: High-dose ISDN
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose ISDN
Study: 128287
Drug: Measles-mumps-rubella trivalent
Normalized name: MEASLES/MUMPS/RUBELLA VIRUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Measles-mumps-rubella trivalent vaccine
Study: 26520396
Drug: 150 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 μg corifollitropin alfa
Study: 23604689
Drug: Zoledronate (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zoledronate (4 mg annually)
Study: 21476064
Drug: Glimepiride (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glimepiride (2 mg single oral dose)
Study: 17374042
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Coping Skills Therapy (CBCST)
Study: 15338385
Drug: Aerobic exercise
Normalized name: camphor
DrugBank: Camphor (DB01744)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aerobic exercise (stationary biking 30 min five times weekly)
Study: 11332146
Drug: Induction chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy with cisplatin, 5‐fluorouracil (5‐FU), leucovorin, and interferon‐alpha 2b (PFL‐IFN) followed by concomitant chemoradiation with 5‐FU, hydroxyurea, and total radiotherapy dose of 7000 cGy (FHX)
Study: 9554570
Drug: Intermittent calcitriol
Normalized name: Calcitriol
DrugBank: Calcitriol (DB00136)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intermittent calcitriol (1,25D) therapy
Study: 9554570
Drug: Daily 1,25D
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily 1,25D therapy
Study: 8017327
Drug: Magnesium aspartate-HCl
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnesium aspartate-HCl (20 mmol Mg/d)
Study: 2472596
Drug: Oral iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral iron therapy (10-day trial)
Study: 2472596
Drug: Oral iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral iron therapy (3 months)
Study: 30875390
Drug: Etelcalcetide 5
Normalized name: etelcalcetide 5 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etelcalcetide 5 mg intravenously three times weekly (TIW) after hemodialysis, with potential dose increases of 2.5 or 5 mg at 4-week intervals to a maximum dose of 15 mg TIW.
Study: 25603851
Drug: Sodium Phosphate
Normalized name: Sodium Phosphate
DrugBank: Sodium nitrate (DB15952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium Phosphate Tablets (SPT)
Study: 10710555
Drug: Insulin infusion
Normalized name: iLet Insulin Infusion 10-Pack Kit Inset
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin infusion (50 mU. kg(‐1). h(‐1))
Study: 10710555
Drug: Low-dose ANP
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose ANP infusion (0.3 pmol. kg(‐1). h(‐1))
Study: 10710555
Drug: High-dose ANP
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose ANP infusion (2 microg/min)
Study: 9181268
Drug: Mibefradil (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mibefradil (100 mg daily for 12 weeks)
Study: 9181268
Drug: Diltiazem CD
Normalized name: Diltiazem Hydrochloride 300 MG Oral Capsule, Extended Release, 24 HR [DILTIAZEM CD]
DrugBank: Diltiazem (DB00343)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Diltiazem CD (360 mg daily for 12 weeks)
Study: 8474278
Drug: Acarbose (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acarbose (3 x 50 mg/day for 1 month, then 3 x 100 mg/day for 2 months)
Study: 4078054
Drug: Povidone-iodine-impregnated polyethylene
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Povidone-iodine-impregnated polyethylene oxide gel (PVPI-POG) dressing
Study: 4078054
Drug: Polyethylene oxide
Normalized name: Polyethylene Oxide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polyethylene oxide gel (POG) dressing
Study: 29310444
Drug: Galcanezumab 5
Normalized name: Galcanezumab
DrugBank: Galcanezumab (DB14042)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Galcanezumab 5 mg
Study: 29310444
Drug: Galcanezumab 50
Normalized name: Galcanezumab
DrugBank: Galcanezumab (DB14042)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Galcanezumab 50 mg
Study: 19590158
Drug: Inhalation of
Normalized name: Ocean brand of sodium chloride Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation of thermal water (TW) for 2 weeks
Study: 24721352
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline inhalation
Study: 11943036
Drug: Oral care
Normalized name: Oral Care Q4 Kit KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral care (tooth brushing after each meal, swabbing with povidone iodine, professional care once a week)
Study: 11943036
Drug: No oral
Normalized name: Beano Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: No oral care
Study: 7664863
Drug: Inhaled platelet‐activating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled platelet‐activating factor (PAF) 225 micrograms
Study: 2673479
Drug: Family therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Family therapy and relatives group (general outcome)
Study: 23668931
Drug: Sotrastaurin 100
Normalized name: Sotrastaurin
DrugBank: Sotrastaurin (DB12369)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sotrastaurin 100 mg b.i.d. plus standard tacrolimus (sTAC; 5‐12 ng/mL)
Study: 23668931
Drug: Sotrastaurin 200
Normalized name: Sotrastaurin
DrugBank: Sotrastaurin (DB12369)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sotrastaurin 200 mg b.i.d. plus standard tacrolimus (sTAC; 5‐12 ng/mL)
Study: 23668931
Drug: Sotrastaurin 300
Normalized name: Sotrastaurin
DrugBank: Sotrastaurin (DB12369)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sotrastaurin 300 mg b.i.d. plus reduced tacrolimus (rTAC; 2‐5 ng/mL)
Study: 23668931
Drug: Enteric-coated mycophenolic
Normalized name: mycophenolic acid
DrugBank: Mycophenolic acid (DB01024)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Enteric-coated mycophenolic acid (MPA) plus standard tacrolimus (sTAC; 5‐12 ng/mL)
Study: 23668931
Drug: Sotrastaurin 200
Normalized name: Sotrastaurin
DrugBank: Sotrastaurin (DB12369)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sotrastaurin 200 mg and 300 mg
Study: 23668931
Drug: Sotrastaurin (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sotrastaurin (all doses)
Study: 18436117
Drug: Pravastatin 40
Normalized name: pravastatin 40 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin 40 mg/day (prava40)
Study: 18436117
Drug: Atorvastatin 10
Normalized name: atorvastatin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 10 mg/day (atorva10)
Study: 18436117
Drug: Atorvastatin 80
Normalized name: atorvastatin 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 80 mg/day (atorva80)
Study: 10857523
Drug: Moderate exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate exercise using arm and bicycle ergometers performed twice a day, 5 times a week, for 14 days, at 60% of maximal heart rate.
Study: 8254142
Drug: Light treatment
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Light treatment administered at the first signs of winter depression
Study: 31276886
Drug: Glyphosate (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glyphosate (1 mg/L)
Study: 31276886
Drug: Roundup (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Roundup (1 mg/L of glyphosate a.e.)
Study: 31276886
Drug: Roundup (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Roundup (1 mg/L of glyphosate a.e.) with androgenic gland
Study: 27738796
Drug: Ondansetron 32-mg
Normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ondansetron 32-mg infusion over 24 hours
Study: 27738796
Drug: Olanzapine wafer
Normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Olanzapine wafer 10 mg once daily plus ondansetron 8 mg IV three times a day
Study: 27738796
Drug: Palonosetron 0.25
Normalized name: palonosetron 0.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Palonosetron 0.25 mg IV
Study: 25894123
Drug: Sirolimus +
Normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Sirolimus + cyclosporine + prednisolone for 3 months followed by sirolimus + prednisolone + mycophenolate mofetil with steroid minimization
Study: 23136856
Drug: Oral miltefosine
Normalized name: Miltefosine
DrugBank: Miltefosine (DB09031)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral miltefosine (100 mg/day for 12 weeks)
Study: 23136856
Drug: Oral miltefosine
Normalized name: Miltefosine
DrugBank: Miltefosine (DB09031)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral miltefosine (100 mg/day for 8 weeks)
Study: 9422899
Drug: Ketoprofen 2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketoprofen 2.0 mg kg-1 i.v.
Study: 9422899
Drug: Ketoprofen 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketoprofen 0.5 mg kg-1 i.v.
Study: 8290458
Drug: OAD cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: OAD cream
Study: 20444751
Drug: Initial combination
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Initial combination therapy with methotrexate (MTX) and ciclosporin (CSA), n=80
Study: 20444751
Drug: Initial monotherapy
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Initial monotherapy with methotrexate (MTX), n=80
Study: 20444751
Drug: Both treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatment groups (MTX + CSA and MTX)
Study: 18635500
Drug: 0.25% bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.25% bupivacaine and 100 mg tramadol (group BT)